55 results about "Large intestinal" patented technology

This invention pertains to a method of promoting gastrointestinal health by ingesting a composition comprising one or more probiotic microorganisms, one or more carbohydrate sources, and one or more resistant protein products. Large intestinal health is benefited by one or more of the following: increased fecal weight, lower fecal pH, increased carbohydrate fermentation, and amelioration of protein fermentation.

A cell culture media composition for support growth of human SI stem cells and epithelium without a feeder layer is presented. The media may also include growth factors including ENR and Y-27632 that support the survival of stem cell spheroid structures. The cell culture media compositions permit rapid growth of human small intestinal (SI) epithelium and stem cells, which leads to specific spheroid cell and enteroid morphology when grown in 3-D culture system.

The invention relates to a compound traditional Chinese medicine preparation with effects of benefiting qi and activating blood circulation for preventing and treating a gastric cancer, and a preparation method thereof, and belongs to the technical field of a traditional Chinese medicine preparation for preventing and treating the gastric cancer. The technical scheme is that the compound traditional Chinese medicine preparation is prepared from the following traditional Chinese medicine components by weight percent: 15-25% of glaucescent fissistigma root, 15-25% of buckwheat leaves, 15-20% of bighead atractylodes rhizome, 10-15% of curcuma zedoary, 10-15% of semen coicis and 10-15% of brucea javanica. The preparation can be prepared into capsules, tablets, powder and the like according to the requirements; the full formula has the effects of benefiting qi and activating blood circulation, and eliminating stagnation to stop pain, and can effectively relieve epigastrium pain, swelling and stuffing, and poor appetite of a patient with gastric carcinoma. The compound traditional Chinese medicine preparation acts on a plurality of organs such as spleen, stomach, large intestines and the like, fully reflects unique understanding of the traditional Chinese medicine on an overall organic body of a human body, achieves the anti-tumor target by conditioning the whole body function, is accurate in curative effect, wide in drug source, low in cost, convenient to produce and take, and significant in treatment effect on the gastric cancer.

To provide a microorganism and an ingredient thereof that contribute to prevention and treatment of immune diseases including allergy, autoimmune diseases and inflammatory bowel diseases (e.g., large-intestinal ulcer), a method of effectively selecting the microorganism, and a method of efficiently inducing immunoregulatory cells that play an important role on maintaining immunological homeostasis using the microorganism or the ingredient thereof. The present invention provides a Lactococcus and an ingredient thereof which induce production of IL-10 from mammalian dendritic or spleen cells, a method of obtaining the microorganism or the ingredient thereof by co-culturing a microorganism such as Lactococcus strains with mammalian dendritic or spleen cells to select a microbial cell having a high IL-10 production ability, a method of selecting the microorganism or the ingredient thereof by co-culturing an intestinal epithelial cell with a microorganism such as the lactic acid bacteria and selecting the cells on the basis of a caspase-1 activity and the ability of inducing the production of IL-18, and a food product or material and an animal feeding stuff or medical and pharmaceutical products which contain the lactic acid bacteria as an effective ingredient.

The invention relates to a nano-drug carrier wrapped by bacterial outer membrane vesicles and a preparation method of the nano-drug carrier. The carrier adopts outer membrane vesicles secreted by Escherichia coli to wrap polydopamine modified doxorubicin-loaded mesoporous silica nanoparticles, and the preparation method comprises the following steps: preparing the doxorubicin-loaded mesoporous silica nanoparticles, modifying the doxorubicin-loaded mesoporous silica nanoparticles by polydopamine, and extracting and purifying the outer membrane vesicles of bacteria. And preparing the nano-drug carrier OMVs-NPs wrapped by the outer membrane vesicles of the bacteria. The prepared OMVs-NPs can prevent the medicine from being released too early in a biological environment, outer membrane vesicles secreted by Escherichia coli have an adsorption effect on intestinal tracts, the OMVs-NPs serve as a biological outer membrane of a novel nano preparation, intestinal absorption of medicine carrying nanoparticles can be improved, the medicine is released after tumor cells are targeted, and the bioavailability of the medicine is improved.

In view of the finding that keeping a healthy body is fundamental for overcoming cancer, it is an object of the present invention to provide a nutritious composition that is effective in suppressing mutagenic substances and promoting good health. The composition also suppresses large intestinal cancer. The composition includes dietary fiber in a range of 15 wt % to 30 wt % in respect to the total amount of composition which is contained in dried koji fine powder that includes dead fungi of Aspergillus and active enzyme produced by the Aspergillus.

A tumor marker detection method, which is a tumor marker detection method for diagnosing colorectal cancer and colorectal adenoma comprising the following steps: a) collecting feces and freezing it; The step of homogenizing the frozen feces in the presence of the suspension to prepare the suspension; c) the step of extracting RNA from the obtained sample for RNA extraction; d) the step of reverse-transcribing the extracted RNA to obtain cDNA; e) a step of amplifying the obtained cDNA, and f) a step of detecting the amplified cDNA, characterized in that the tumor marker is at least one tumor marker selected from COX-2, SNAIL, and MMP-7 ( But exclude only any one of COX-2 or MMP-7).

The present invention is directed to a method for diagnosing large intestinal cancer and / or polyp and a method for observing postoperative course or monitoring recurrence thereof, wherein each method includes detecting cystatin SN protein by use of an anti-cystatin SN antibody. The present invention is able to provide a kit for assaying cystatin SN, which can be used, in a simple manner, in a diagnosis performed prior to conventional barium enema examination and endoscopic examination which impose burdens on patients; as an indicator of metastasis and recurrence; and in the evaluation of therapeutic effects. The present invention provides a method for diagnosing or monitoring large intestinal cancer and / or polyp which can be performed in a simple manner, and thus can allow to design a new regimen rapidly.

An in vitro microfluidic intestine on-chip is described herein that mimics the structure and at least one function of specific areas of the gastrointestinal system in vivo. In particular, a multicellular, layered, microfluidic intestinal cell culture, which is some embodiments is derived from patient's enteroids-derived cells, is described comprising L cells, allowing for interactions between L cells and gastrointestinal epithelial cells, endothelial cells and immune cells. This in vitro microfluidic system can be used for modeling inflammatory gastrointestinal autoimmune tissue, e.g., diabetes, obesity, intestinal insufficiency and other inflammatory gastrointestinal disorders. These multicellular-layered microfluidic intestine on-chips further allow for comparisons between types of gastrointestinal tissues, e.g., small intestinal duodenum, small intestinal jejunum, small intestinal ileum, large intestinal colon, etc., and between disease states of gastrointestinal tissue, i.e. healthy, pre-disease and diseased areas. Additionally, these microfluidic gut-on-chips allow identification of cells and cellular derived factors driving disease states and drug testing for reducing inflammation.

To provide a microorganism and an ingredient thereof that contribute to prevention and treatment of immune diseases including allergy, autoimmune diseases and inflammatory bowel diseases (e.g., large-intestinal ulcer), a method of effectively selecting the microorganism, and a method of efficiently inducing immunoregulatory cells that play an important role on maintaining immunological homeostasis using the microorganism or the ingredient thereof. The present invention provides a Lactococcus and an ingredient thereof which induce production of IL-10 from mammalian dendritic or spleen cells, a method of obtaining the microorganism or the ingredient thereof by co-culturing a microorganism such as Lactococcus strains with mammalian dendritic or spleen cells to select a microbial cell having a high IL-10 production ability, a method of selecting the microorganism or the ingredient thereof by co-culturing an intestinal epithelial cell with a microorganism such as the lactic acid bacteria and selecting the cells on the basis of a caspase-1 activity and the ability of inducing the production of IL-18, and a food product or material and an animal feeding stuff or medical and pharmaceutical products which contain the lactic acid bacteria as an effective ingredient.

The invention discloses a pharmaceutical composition for treating constipation, which is prepared from the following raw materials in parts by weight: 3-4 parts of plantago polysaccharide, 8-10 parts of bee pollen, 2-4 parts of probiotic agent, konjac Glucomannan 1-2 parts, sodium alginate 1-2 parts, calcium chloride 1-2 parts. On the one hand, the konjac glucomannan added in the present invention can promote intestinal peristalsis; Sugar and sodium alginate are compounded to embed probiotics, which can avoid the inactivation of probiotics in the stomach and achieve the effect of probiotics colonizing the intestinal tract; in addition, plantago polysaccharides, bee pollen, and probiotic bacterial agents in the present invention , Konjac glucomannan cooperate with each other to soften the stool, promote gastrointestinal motility, restore the balance of intestinal flora, and achieve the effect of treating constipation from the root.

The invention relates to application of drug composition product in curing diseases of the respiratory system. The effect of the drug composition product on curing the respiratory system diseases caused by infection of escherichia coli and klebsiella pneumoniae is better than the effect of the drug composition product on curing urinary system diseases caused by infection of the escherichia coli and the klebsiella pneumoniae.

Provided is a method for detecting aberrant crypt foci (ACF) by analyzing a region of interest in large intestinal tissue at a molecular level. That is, provided are: a method for detecting ACF using at least one molecule, the expression level of which is elevated specifically to ACF, as an ACF detection marker, and detecting the ACF detection marker in a region of interest in large intestinal tissue, wherein the at least one molecule is selected from the group consisting of Met, Cdh1, Ctnnb1 and GSTp; an ACF detection marker which is a marker for detecting ACF in human-originated large intestinal tissue and is Met, Cdh1, Ctnnb1 or GSTp; and a method for evaluating the risk of colorectal cancer and colorectal adenoma in a human body, which comprises detecting ACF in a region of interest in large intestinal tissue from a subject using the aforementioned ACF detection method and evaluating the risk of colorectal cancer and colorectal adenoma in the subject on the basis of the results of the detection.

The present invention provides a class of compounds, which includes enantiomers and pharmaceutically acceptable salts thereof, that selectively and effectively inhibit Hakai-mediated ubiquitination, preferably without affecting Hakai protein levels, thereby representing excellent anti-cancer drugs useful in the treatment of a variety of cancers, such as carcinomas, in particular, tumors arising from the epithelial layers of the gastrointestinal track including month (oral cancer), esophagus, stomach, and small and large intestines (such as rectal or colon cancer). It also includes skin cancer, mammary gland (breast cancer), pancreas cancer, lung cancer, head and neck cancer, liver cancer, ovary cancer, cervix cancer, uterus cancer, gallbladder cancer, penile cancer, and urinary bladder cancer (such as renal, prostate or bladder cancer).